I came across this small Analytical Article in The Economic Times which speaks a lot about Alembic pharma. The last paragraph reads as follows which is exactly in line with what our most respected Dr Hitesh has been telling.
From a valuation perspective, Alembic remains one of the cheapest bets amongst its peers, trading at a PE ratio of 18.7x on FY21 estimates. With healthy EBITDA margins of 31% in Q1FY21 and superior ROEs of 26.8%, Alembic remains a worthy Re-rating candidate, Vaibhav Shah, managing director of Monarch Networth Capital said.
Now since API is the flavour of the season, 
Was trying to understand it’s API making capability. It has 3 API plants- all USFDA complied and it appears it has increased its API capacity from 30 metric Tonnes per month to 100 metric Tonnes per month and awaiting for Govt approval to enhance to 250 metric tonnes per month…
From Alembic Pharma’s website , it claims it has filed 84 API’s with USDMF, 34 with Europe , 15 with Japan, 35 with China,22 with South Korea, 25 with Mexico.
Well , what are these API’s??? I confirmed the name of all these API’s from a third party website…so it appears that Alembic aiming to be a major player in API business considering its growth potential …
Needless to say , On formulation front, Alembic has already proved its worth over the years with its wide range of formulations presence in many segments both Chronic and Acute and it continues to enjoy leadership position in some of these drugs:
(1) Sartan’s called ARB’s are preferred as popular Anti Hypertension drugs due to least side effects.
(2) Sartan standalone being prescribed for kidney disease and for reducing proteinuria.
(3) Sartan nowadays being prescribed for all Diabetes patients as a standard protocol for Renal protection and blood pressure control along with Blood sugar lowering drugs.
(4) Its respiratory portfolio consisting of antibiotic range of Microlides such as Azithromycin, Clarithromycin, Erythromycin, Roxithromycin and a wide range of Cough and Cold medicines.
We need to see how Alembic delivers in coming quarters. With Promoter stake of 73% and now that it has cleared it’s debt from the QIP…
https://www.alembicpharmaceuticals.com/active-pharmaceutical-ingredients/
Discl: Invested and I may be biased. Please apply due diligence before putting your hard earned money in stock market.